Clinical trial
A Study to Assess the Long-Term Safety of Tacrolimus Cream in the Treatment of…
NCT00293917 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00293917 |
|---|---|
| Title | A Study to Assess the Long-Term Safety of Tacrolimus Cream in the Treatment of Psoriasis |
| Official title | A Phase 3, Long-Term, Open Label Study to Evaluate the Safety of Twice Daily Tacrolimus Cream-B 0.1% in the Treatment of Psoriasis |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Astellas Pharma US, Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Tacrolimus Cream |
| Enrollment | 658 |
| Start date | Jan 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Feb 20, 2006 |
| Last update posted | Feb 13, 2008 |
| Countries | Canada, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: